Biopharmaceutical Company Expands Clinical Trials For Texas A&M-Developed Angelman Syndrome Treatment
August 16, 2022
August 16, 2022
COLLEGE STATION, Texas, Aug. 16 (TNSres) -- Texas A&M University's College of Veterinary Medicine and Biomedical Sciences issued the following news release:
A treatment for a rare disease that was researched and developed in the laboratory of Texas A&M School of Veterinary Medicine & Biomedical Sciences (VMBS) associate professor Scott Dindot has not only produced encouraging interim data from a phase 1/2 clinical trial in the United States, United Kingdom, and Cana . . .
A treatment for a rare disease that was researched and developed in the laboratory of Texas A&M School of Veterinary Medicine & Biomedical Sciences (VMBS) associate professor Scott Dindot has not only produced encouraging interim data from a phase 1/2 clinical trial in the United States, United Kingdom, and Cana . . .